PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis

• M Okada,
• J Weinmann-Menke,
• C Arriens,
• R Furie,
• A Jones-Leone,
• RA Levy,
• JA Gilbride,
• N Yang

Affiliations

M Okada

Department of Orthopaedic Surgery, UBC, Vancouver, Canada

J Weinmann-Menke

1Johannes Gutenberg University I. Department of Nephrology and Rheumatology, Mainz, Germany

C Arriens

3Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology, Oklahoma City, USA

R Furie

4Hofstra North Shore-LIJ School of Medicine, Rheumatology, Great Neck, USA

A Jones-Leone

4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA

RA Levy

4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA

JA Gilbride

5GlaxoSmithKline, RandD Biostatistics ~ Stevenage ~ UK

N Yang

7First Affiliated Hospital, Department of Rheumatology, Sun Yat-sen University ~ Guangzhou ~ China